Ethics approval
CDI
APPENDIX
Ethics approval to conduct this study was obtained from the Conjoint Health Research Ethics Board at the University of Calgary (REB16-1834). Specifically, a waiver of individual consent for in-hospital administration of probiotics to the patients in the quasi-experimental, stepped wedge, cluster- randomized controlled trial (Prevent CDI-55 +), was granted. However, patients received an information package upon Bio-K + administration containing information on the initiative, use of probiotics, their effectiveness in preventing CDI, and their safety. In addition, a waiver of consent was also granted for health information access, consistent with the provisions of the Health Information Act of Alberta. Consent was obtained at the time of agreement to participate by individuals in the focus groups. The information sheet that was provided to all focus group participants is provided in Appendix 